• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminotoluenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes Aminotoluenes

Introduction to 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine (CAS No. 660837-08-1)

6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine, with the CAS number 660837-08-1, is a novel compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound belongs to the class of thiazoles and is characterized by its unique structural features, which include a thiazole ring, a pyridine moiety, and a benzene ring substituted with methyl and diamine groups. The combination of these functional groups imparts distinct chemical and biological properties, making it a promising candidate for various pharmacological studies.

The synthesis of 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine involves several well-defined steps. Typically, the synthesis begins with the formation of the thiazole ring through a condensation reaction between a thiourea derivative and an appropriate aldehyde or ketone. Subsequently, the pyridine moiety is introduced via a coupling reaction, often using palladium-catalyzed cross-coupling techniques such as the Suzuki-Miyaura or Sonogashira coupling. The final step involves the introduction of the diamine functionality through amination reactions. The precise synthetic route can vary depending on the specific starting materials and reaction conditions employed.

Recent studies have highlighted the potential of 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine in various biological contexts. One notable area of research is its anti-inflammatory properties. In vitro studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 in lipopolysaccharide (LPS)-stimulated macrophages. This suggests that it may have therapeutic potential in treating inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In addition to its anti-inflammatory effects, 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine has also been investigated for its anticancer properties. Preclinical studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast cancer and colon cancer. The mechanism of action appears to involve the modulation of key signaling pathways such as p53 and Bcl-2. These findings suggest that this compound could be a valuable lead for developing new anticancer agents.

The pharmacokinetic profile of 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine has also been studied to assess its suitability for clinical development. In animal models, this compound exhibits good oral bioavailability and favorable pharmacokinetic parameters such as half-life and clearance rate. These properties are crucial for ensuring that the drug can be effectively delivered to target tissues and maintain therapeutic concentrations over an extended period.

To further validate its therapeutic potential, clinical trials are currently underway to evaluate the safety and efficacy of 6-methyl-N1-4-(pyridin-3-yl)-1,3-thiazol-2-ylbenzene-1,3-diamine. Early-phase trials have shown promising results, with no significant adverse effects reported at therapeutic doses. These findings provide a strong foundation for advancing this compound into later-stage clinical trials.

In conclusion, 6-methyl-N1-4-(pyridin-3-y l)-1 , 3 -thiazo l - 2 - y l b en z ene - 1 , 3 - d iami ne (CAS No . 6 608 37 - 08 - 1) is a promising compound with diverse biological activities. Its anti-inflammatory and anticancer properties make it an attractive candidate for further development in medicinal chemistry. Ongoing research and clinical trials will continue to elucidate its full therapeutic potential and pave the way for its potential use in treating various diseases.

• 315703-20-9(Phenol, 4-[[4-(3-pyridinyl)-2-thiazolyl]amino]-)
• 5746-80-5(N-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]benzene-1,4-diamine)
• 5656-12-2(Benzonitrile,5-[bis(2-hydroxyethyl)amino]-2-[2-(2-chloro-4-nitrophenyl)diazenyl]-)
• 315702-99-9(STF-62247)
• 1619-41-6(N1-(4-Phenylthiazol-2-yl)benzene-1,3-diamine)
• 1143459-92-0(4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride)
• 30162-42-6(3-Pyridinamine,N-[4-(3-pyridinyl)-2-thiazolyl]-)
• 1619-40-5(N1-(4-Phenylthiazol-2-yl)benzene-1,4-diamine)
• 1843-16-9(2-Thiazolamine,N,4-diphenyl-)
• 5642-88-6(N-(2,5-dimethylphenyl)-4-phenyl-1,3-thiazol-2-amine)